Benzinga | Aug 19, 2021 09:37AM EDT

Aegis Capital Maintains Buy on DarioHealth, Lowers Price Target to $28

Aegis Capital analyst Nathan Weinstein maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $35 to $28.